Developments in metastatic pancreatic cancer: is gemcitabine still the standard? - Wikidata - wikimedia - TriplyDB

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

http://www.wikidata.org/entity/Q35776091

about

Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma.PEG Grafted-Nanodiamonds for the Delivery of Gemcitabine.Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer.Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer.Effect of arenobufagin on human pancreatic carcinoma cells.Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma.Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.

P2860

Q26739910-AA21A0E5-3125-4DC0-BB41-309B97D1076A Q33623176-25038D69-5126-49AB-98FD-2077EB27D749 Q33887021-542DBFE4-FA8D-491E-9E62-CAE89942564E Q33981400-0DD4C6E3-358D-4C60-8633-FF0770B176F0 Q34996501-508512EA-B9AD-4BB3-B837-63987AD574B0 Q35605388-99CFD0A9-4436-4C65-8A93-C5621C44DE32 Q35857561-799278B7-2C34-43FB-BD6A-367E20B8E4E9 Q37253577-13F58CF3-5E4E-4B34-BFF1-EE421F8E93E3 Q37285560-092B23EC-AD0E-4E89-A99C-7FBDC11C18CD Q37357401-544F6B45-639C-4AB1-9CFC-3AD2B7401318 Q37625297-DAA968DD-D80E-4A72-A407-8D40DD5492AA Q37688898-29ADED06-292F-456A-B446-81D4BC89A924 Q38658009-AF98B742-D978-47DF-BF5C-5DBDF2CA3661 Q38733010-A47A5D27-4938-4B42-9B2A-B7BED7963BBF Q38783344-73C39932-93DA-424E-A85C-172CFBD6653A Q41934085-1629B12F-4539-4A80-BDA7-5D81D82803BF Q47128109-1843576E-C9A5-448A-8CB5-1548ABAB1060 Q47170368-B88ECAA3-2A4B-4334-8584-70D3D57B8BBF Q48157840-06F763DA-526E-4764-AE43-11844FA9360B Q54210630-B6BAC24B-5E8B-4520-927C-23E75534F271

P2860

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

http://www.wikidata.org/entity/Q35776091

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@ast

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@en

type

label

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@ast

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@en

prefLabel

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@ast

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@en

P1433

Q35776091-6238B94B-2038-4705-8B2C-F1CED9E6B159

P1476

Q35776091-8D3A0212-7702-4B9C-8D5D-5305D894DBA5

P2093

Q35776091-1B4D4EA0-3803-46B5-B3DC-4FA4080D451D

Q35776091-2F58738E-033E-46D6-B116-6D731B9B46DE

Q35776091-D71D12C0-1577-4628-98D6-1658CF278EE3

P2860

Q35776091-013CB074-29E7-448D-B6D7-890BE0FFD81E

Q35776091-034264E3-274E-4324-BCAC-E4D7C6CBF313

Q35776091-03B1E00C-69B2-442C-8EAB-93DF643F152A

Q35776091-0841A11B-3FF3-466E-81BA-E12FA15077DB

Q35776091-0A5DDA80-8289-4409-8E3E-6B552C4F2EB8

Q35776091-0A6F0FBC-58FD-49FB-827D-6F98FC472CB8

Q35776091-0D796E1E-93CF-487D-89D0-1F7D15EE6A38

Q35776091-14A34A44-1BAB-4997-A5A0-6CD04C354D1D

Q35776091-1823E392-B328-4045-AABB-06F0B4CEF9FF

Q35776091-2004B163-30DC-43BC-9D46-FB7E16B099FD

P304

Q35776091-B089722D-F65E-414C-8AED-CE7034082422

P31

Q35776091-96D242CE-9A82-408C-8E58-51A00025628E

P356

Q35776091-807BB4C1-18D5-471B-B518-03BD88A350A7

P407

Q35776091-0C7E477F-0286-4845-8DE5-D01BAF5A9DB2

P433

Q35776091-E5CEC903-98EB-42B3-A8B6-7BFAA761DA72

P478

Q35776091-341D6D56-8CF1-4FE3-AD8A-5098F2623DB6

P577

Q35776091-DFB6EF7E-F3AF-4242-B768-FA7B0A2F4473

P5875

Q35776091-978B0F2C-293D-45A7-8BF9-9747FB16EC71

P698

Q35776091-1A683C26-A0C7-419C-BE4F-E7B3C858D7BA

P932

Q35776091-5D8F13AB-5E31-4B03-8ACF-414A2DB82668

P356

P1433

World Journal of Gastroenterology

P1476

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@en

P2093

Bi-Xia Liu

http://www.w3.org/2001/XMLSchema#string

Jie-Er Ying

http://www.w3.org/2001/XMLSchema#string

Li-Ming Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

Novel approaches to target pancreatic cancer.

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

P304

736-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V18.I8.736

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221867787

http://www.w3.org/2001/XMLSchema#string

P698

22371633

http://www.w3.org/2001/XMLSchema#string

P932

3286136

http://www.w3.org/2001/XMLSchema#string